Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Suppression of melanoma by mice lacking MHC-II: Mechanisms and implications for cancer immunotherapy

The Journal of Experimental Medicine(2024)10.1084/jem.20240797Source: DataRank Database

Suppression of melanoma by mice lacking MHC-II: Mechanisms and implications for cancer immunotherapy is a research paper published in The Journal of Experimental Medicine (2024). On theSindex it has a DataRank of 0. It has been cited 8 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access8 citations

Download PDF

Cite:

Linked data & code

refseq

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 1.25)OA: hybridTopics (55)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (15)

Dawson Medler ORCID,Jianhui Wang ORCID,Rachel Browning ORCID,Aijie Liu ORCID,Sara Schneider ORCID

Live enrichment

PubMed:39470607 PMC:PMC11528124 OpenAlex:https://openalex.org/W4403851258

National Institutes of Health

Grant: AI125581

National Institutes of Health

Grant: CA258602

NCI NIH HHS

Grant: R01 CA258602

NIAID NIH HHS

Grant: R01 AI125581

National Institutes of Health

Grant: 5R01AI125581-03

Automated Forward Genetic Analysis of Adaptive Immunity

National Institutes of Health

Grant: 1R01CA258602-01A1

Cancer Resistant Mice

University of Texas Southwestern Medical Center

FWCI

1.25

Citation Percentile

0.8%

Citation Trend

2025

hybridLicense: other-oa

journalhttps://rupress.org/jem/article-pdf/221/12/e20240797/1933953/jem_20240797.pdf

publisherhttps://rupress.org/jem/article-pdf/221/12/e20240797/1933953/jem_20240797.pdf

publisherhttps://rupress.org/jem/article-pdf/doi/10.1084/jem.20240797/1933953/jem_20240797.pdf

journalhttps://doi.org/10.1084/jem.20240797

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39470607

Fields of Study

Immunotherapy and Immune ResponsesImmune Cell Function and InteractionCancer Immunotherapy and Biomarkers03 medical and health sciences0302 clinical medicineAnimalsMice, Inbred C57BLImmunotherapyDendritic CellsMiceCD8-Positive T-LymphocytesMelanomaMelanoma, ExperimentalHistocompatibility Antigens Class IIT-Lymphocytes, RegulatoryImmune Checkpoint InhibitorsCell Line, Tumor

MeSH Terms

Immune Checkpoint InhibitorsAnimalsHistocompatibility Antigens Class IIDendritic CellsImmunotherapyMelanomaMelanoma, ExperimentalMice, Inbred C57BLCD8-Positive T-LymphocytesCell Line, TumorT-Lymphocytes, RegulatoryMice

Keywords

MelanomaCancer researchCD8Immune systemImmunotherapyMHC class ICancerMajor histocompatibility complexCancer immunotherapyImmunologyCyclin-dependent kinase 1BiologyMedicineCell cycleGeneticsMelanoma, ExperimentalHistocompatibility Antigens Class IIDendritic CellsCD8-Positive T-LymphocytesT-Lymphocytes, RegulatoryArticleMice, Inbred C57BLMiceCell Line, TumorAnimalsImmune Checkpoint Inhibitors

Sustainable Development Goals

SDG 0: Good health and well-being